Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
OptiBiotix Health said subsidiary ProBiotix Health had signed a license agreement with Kappa Bioscience.
The agreement covered the use of OptiBiotix Health's blood pressure-reducing probiotic strain Lactobacillus plantarum in a new application area within cardiovascular health.
It covered 27 countries, largely in Europe, but also included Russia and Singapore.=
At 8:51am: (LON:OPTI) Optibiotix Health Plc share price was +1p at 85p